Long-term depot-medroxyprogesterone acetate and bone mineral density
The association between long-term use of depot-medroxyprogesterone acetate (DMPA) and bone mineral density (BMD) has been controversial, as seen in three case-control studies in New Zealand, Thailand, and the United Kingdom. In the present case-controlled study of BMD, a group of 67 Chinese women who had used DMPA from 5-15 years was compared with 218 women of the same age range who had not used any steroidal hormones. DMPA users were found to have a significantly lower BMD at lumbar vertebra (L2-4) (0.93 g/cm2), neck of femur (0.69 g/cm2), trochanter (0.59 g/cm2), and Ward's triangle (0.58 g/cm2), as compared with the control group, whose corresponding BMD values were 1.03 g/cm2, 0.83 g/cm2, 0.71 g/cm2, and 0.78 g/cm2, respectively (p < 0.001). The average percentage of bone loss per year was estimated to be 1.1% in L2-4, 2.3% in neck of femur, 2.4% in trochanter, and 3.5% in Ward's triangle. The percentage of bone loss in L2-4 was found to be more pronounced with age. This study provided information that the use of DMPA in a Chinese group for > 5 years in associated with bone loss, and a prospective study is needed to confirm these data, which are different from two case-control studies.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1999 |
|---|---|
| Erschienen: |
1999 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Contraception - 59(1999), 1 vom: 03. Jan., Seite 25-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tang, O S [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 10.08.1999 Date Revised 26.08.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM102744416 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM102744416 | ||
| 003 | DE-627 | ||
| 005 | 20231222124910.0 | ||
| 007 | tu | ||
| 008 | 231222s1999 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0343.xml |
| 035 | |a (DE-627)NLM102744416 | ||
| 035 | |a (NLM)10342083 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tang, O S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term depot-medroxyprogesterone acetate and bone mineral density |
| 264 | 1 | |c 1999 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 10.08.1999 | ||
| 500 | |a Date Revised 26.08.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The association between long-term use of depot-medroxyprogesterone acetate (DMPA) and bone mineral density (BMD) has been controversial, as seen in three case-control studies in New Zealand, Thailand, and the United Kingdom. In the present case-controlled study of BMD, a group of 67 Chinese women who had used DMPA from 5-15 years was compared with 218 women of the same age range who had not used any steroidal hormones. DMPA users were found to have a significantly lower BMD at lumbar vertebra (L2-4) (0.93 g/cm2), neck of femur (0.69 g/cm2), trochanter (0.59 g/cm2), and Ward's triangle (0.58 g/cm2), as compared with the control group, whose corresponding BMD values were 1.03 g/cm2, 0.83 g/cm2, 0.71 g/cm2, and 0.78 g/cm2, respectively (p < 0.001). The average percentage of bone loss per year was estimated to be 1.1% in L2-4, 2.3% in neck of femur, 2.4% in trochanter, and 3.5% in Ward's triangle. The percentage of bone loss in L2-4 was found to be more pronounced with age. This study provided information that the use of DMPA in a Chinese group for > 5 years in associated with bone loss, and a prospective study is needed to confirm these data, which are different from two case-control studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Asia | |
| 650 | 4 | |a Biology | |
| 650 | 4 | |a China | |
| 650 | 4 | |a Comparative Studies | |
| 650 | 4 | |a Contraception | |
| 650 | 4 | |a Contraceptive Agents, Female--pharmacodynamics | |
| 650 | 4 | |a Contraceptive Agents, Progestin--pharmacodynamics | |
| 650 | 4 | |a Contraceptive Agents--pharmacodynamics | |
| 650 | 4 | |a Contraceptive Methods--side effects | |
| 650 | 4 | |a Demographic Factors | |
| 650 | 4 | |a Depo-provera--pharmacodynamics | |
| 650 | 4 | |a Developing Countries | |
| 650 | 4 | |a Eastern Asia | |
| 650 | 4 | |a Family Planning | |
| 650 | 4 | |a Injectables--side effects | |
| 650 | 4 | |a Longterm Effects--women | |
| 650 | 4 | |a Medroxyprogesterone Acetate--pharmacodynamics | |
| 650 | 4 | |a Physiology | |
| 650 | 4 | |a Population | |
| 650 | 4 | |a Population Dynamics | |
| 650 | 4 | |a Research Methodology | |
| 650 | 4 | |a Research Report | |
| 650 | 4 | |a Skeletal Effects--women | |
| 650 | 4 | |a Studies | |
| 650 | 4 | |a Time Factors | |
| 650 | 4 | |a Women | |
| 650 | 7 | |a Contraceptive Agents, Female |2 NLM | |
| 650 | 7 | |a Medroxyprogesterone Acetate |2 NLM | |
| 650 | 7 | |a C2QI4IOI2G |2 NLM | |
| 650 | 7 | |a Calcium |2 NLM | |
| 650 | 7 | |a SY7Q814VUP |2 NLM | |
| 700 | 1 | |a Tang, G |e verfasserin |4 aut | |
| 700 | 1 | |a Yip, P |e verfasserin |4 aut | |
| 700 | 1 | |a Li, B |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Contraception |d 1972 |g 59(1999), 1 vom: 03. Jan., Seite 25-9 |w (DE-627)NLM000108367 |x 1879-0518 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:1999 |g number:1 |g day:03 |g month:01 |g pages:25-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 1999 |e 1 |b 03 |c 01 |h 25-9 | ||